Genzyme Cleans Up Allston Factory

Xconomy Boston — 

Genzyme (NASDAQ: GENZ), the Cambridge, MA-based maker of drugs for rare genetic diseases, said today it has finished sanitizing its biotech drugmaking plant in Allston, MA and is on schedule to re-start production there this month. Last month, the company spotted a viral contaminant that forced it to halt production. The company is now preparing to deal with 6-8 week supply shortages of two of its best-selling drugs, Cerezyme and Fabrazyme. Sales of Cerezyme are now expected to run between $750 million to $1 billion this year, instead of the company’s prior forecast of $1.25 to $1.275 billion.